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Abstract
 
Granzyme B (GrB), a serine protease with substrate specificity similar to the caspase family, is a
major component of granule-mediated cytotoxicity of T lymphocytes. Although GrB can di-
rectly activate caspases, it induces apoptosis predominantly via Bid cleavage, mitochondrial
outer membrane permeabilization, and cytochrome c release. To study the molecular regula-
tors for GrB-mediated mitochondrial apoptotic events, we used a CTL-free cytotoxicity sys-
tem, wherein target cells are treated with purified GrB and replication-deficient adenovirus
(Ad). We report here that the Bcl-2 proapoptotic family member, Bak, plays a dominant role
in GrB-mediated mitochondrial apoptotic events. A variant of Jurkat cells, deficient in Bak ex-
pression, was resistant to GrB/Ad-mediated apoptosis, as determined by lack of membranous
phosphatidylserine exposure, lack of DNA breaks, lack of mitochondrial outer membrane per-
meabilization, and unchanged expression of inner mitochondrial membrane cardiolipin. The
resistance of Bak-deficient cells to GrB/Ad cytotoxicity was reversed by transduction of the
Bak gene into these cells. The requirement for both Bid and Bak, was further demonstrated in
a cell-free system using purified mitochondria and S-100 cytosol. Purified mitochondria from
Bid knockout mice, but not from Bax knockout mice, failed to release cytochrome c in re-
sponse to autologous S-100 and GrB. Also, Bak-deficient mitochondria did not release cyto-
chrome c in response to GrB-treated cytosol unless recombinant Bak protein was added. These
results are the first to report a role for Bak in GrB-mediated mitochondrial apoptosis. This
study demonstrates that GrB-cleaved Bid, which differs in size and site of cleavage from
caspase-8-cleaved Bid, utilizes Bak for cytochrome c release, and therefore, suggests that defi-
ciency in Bak may serve as a mechanism of immune evasion for tumor or viral infected cells.
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Introduction
 
CTLs and natural killer (NK)
 
*
 
 cells induce apoptosis in tar-
get cells by two major mechanisms, including the engage-
ment of the Fas receptor on target cells or the release of
cytolytic granules into target cells. Ligation of the Fas re-
ceptor on target cells by Fas ligand on cytotoxic cells ini-
tiates a death cascade, which involves activation of caspase-8
as an initiator protease (1). The second major mechanism
for T and NK cell cytotoxicity utilizes cytolytic granules,
which contain perforin and granzymes that are secreted
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Abbreviations used in this paper:
 
 Ad, adenovirus; CMXRos, chloro-
methyl X-rosamine; Cox IV, cytochrome c oxidase IV; DFF, DNA frag-
mentation factor; GrB, granzyme B; GST, glutathione S-transferase;
ICAD, inhibitor of caspase-activate DNase; MIB, mitochondria buffer;
NAO, nonyl acrydine orange; NK, natural killer; PARP, poly-(ADP-ribose)
polymerase; tBid, truncated Bid; TRAIL, TNF-related apoptosis-induc-
ing ligand; Z-VAD-FMK, Cbz-Val-Ala-Asp-fluoromethyl ketone. 
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into target cells (2, 3). Studies in gene knockout mice have
indicated that perforin is essential for the granule exocytosis
mechanism of cell death (4). Although, perforin by itself
cannot induce apoptosis, it allows granzymes, cosecreted
serine proteases, to access their substrates. Perforin is re-
quired for the disruption of granzyme-containing target cell
endosomes, a function that can be substituted for by endo-
somolytic agents, such as adenovirus (Ad, reference 5), liste-
riolysin, and pneumococcal pneumolysin (6).
Granzyme B (GrB), the prototypic member of the
granzyme family of serine proteases, shares substrate speci-
ficity with caspases for cleavage after aspartate residues (7).
GrB has been reported to cleave caspases, including -3, -6,
-7, -8, and -10 in vitro (2, 8–10). It has been assumed that
it can initiate apoptosis at multiple points along the cas-
pase-dependent apoptotic cascade (11, 12). However, a hi-
erarchical manner has been observed for the in vivo activ-
ity of this enzyme, with preference for specific substrates
(13). GrB can also induce death through a caspase-inde-
pendent mechanism, that is inhibitable by Bcl-2 (14). Con-
sistent with these observations, recent reports have sug-
gested that the preferred mechanism for rapid induction of
apoptosis by GrB is mediated by cleavage of Bid, which
initiates a mitochondrial apoptotic cascade (13, 15–17).
Bid, a BH3-only proapoptotic Bcl-2 family member, is
cleaved by caspase-8 (18, 19), lysosomal proteases (20), or
GrB (13, 15–17). Although cleaved at different sites (20),
each of the resultant truncated Bids (tBids) translocates to
the mitochondrial outer membrane, where it triggers the
release of mitochondrial intermembrane cytochrome c.
Release of cytochrome c is essential for the mitochondrial
apoptotic cascade (21). Upon its release, cytochrome c, in
concert with Apaf-1 and dATP, activates caspase-9, lead-
ing to the subsequent activation of caspase-3 (22–24). As
initiation of apoptosis by GrB requires direct cleavage of
Bid, but not direct granzyme-B–mediated caspase activa-
tion (15), it thus appears that the cytotoxicity mediated by
GrB is regulated by internal mitochondrial mechanisms for
releasing cytochrome c.
The mitochondrial mechanisms responsible for cyto-
chrome c release have not yet been fully elucidated. How-
ever, using Bak-knockout mice it has been observed that
mitochondrial Bak is required for caspase 8-cleaved Bid to
induce release of cytochrome c (25). Once inserted into the
mitochondrial outer membrane, this fragment of Bid does
not function as a poreforming protein, but as a membrane
targeted death ligand capable of inducing oligomerization
of Bak. It has been proposed that oligomerized Bak serves
as a mitochondrial outer membrane pore for cytochrome c
efflux (26).
It has also been suggested that tBid acts partly by induc-
ing conformational changes in Bax and its translocation to
the mitochondria (27, 28). Therefore, it is possible that
both Bid and Bax are required for mitochondrial response
to GrB. Cytosolic Bax in Jurkat cells has been reported to
translocate to the mitochondria in response to GrB (16).
However, its requirement for GrB-mediated cytochrome c
release has not been addressed. Also, GrB cleaves Bid at a
different site than caspase-8, and therefore, these two forms
of cleaved Bid might have different binding partners upon
translocation to the mitochondria. The requirement for
Bak by BrB-cleaved Bid in mitochondrial cytochrome c
release has also not been addressed.
In the current study, we have used a variant Jurkat cell
line deficient in Bak to elucidate the role of Bak in the
GrB-mediated mitochondrial apoptotic cascade. We have
also used three loss-of-function mouse models, Bid defi-
ciency, Bax deficiency, and combined Bid and Bax defi-
ciency, to determine the relevance of Bid and Bax for the
mitochondrial response to GrB. This study has established a
regulatory role for Bak downstream of Bid in the mito-
chondrial mechanism for releasing cytochrome c in re-
sponse to GrB, a prominent component of CTL and NK
cytolytic granules.
 
Materials and Methods
 
Reagents.
 
Anti–human Bak Abs were from Oncogene (Ab-1,
mouse clone AMO3, generated against recombinant Bak
 
 
 
C),
BD PharMingen (Ab-2, polyclonal Ab generated against recom-
binant Bak
 
 
 
C), Biosource International (Ab-3, polyclonal Ab
generated against synthetic peptide corresponding to amino acids
23–37 of human Bak) and Accurate Chemical (Ab-4, polyclonal
Ab generated against recombinant Bak
 
 
 
C). Anti–
 
 
 
-actin mAb
(clone AC-15) was purchased from Sigma-Aldrich. Anticyto-
chrome c oxidase IV (Cox IV) Ab was from Molecular Probes;
rabbit anti-Bid Ab was a gift from Xiaodong Wang (Southwest-
ern Medical Center, Dallas, TX). We also used anti-Bid Ab from
BioVision and from Santa Cruz Biotechnology, Inc.; anticaspase-3
was from BD PharMingen; anti-poly-(ADP-ribose) polymerase
(PARP) mAb (C2.10) and Cbz-Val-Ala-Asp-fluoromethyl ke-
tone (Z-VAD-FMK) were from Enzyme System; rabbit anti-
DNA fragmentation factor (DFF)45/inhibitor of caspase-activate
DNase (ICAD) Ab was from ProSci. TNF-related apoptosis-
inducing ligand (TRAIL) protein was from Alexis; cisplatin and
taxol were from Bristol-Myers Squibb; FITC-annexin V and
propidium iodide were from CLONTECH.
 
Preparation of His-tagged tBid and Glutathione S-Transferase-
Bak.
 
Mouse NH
 
2
 
-terminal histidine tagged tBid (Ser
 
76
 
-Asp
 
195
 
)
was expressed by the recombinant plasmid, p84–1, that was gen-
erated by subcloning a PCR amplicon produced from mouse Bid
cDNA. The PCR amplicon generated with the forward primer
5
 
 
 
-GGAATTCCATATGTCTGAAAGTCAGGAAGAAATC-
3
 
 
 
 and the reverse primer 5
 
 
 
-CCGCTCGAGTCAGTC-
CATCTCGTTTCTAAC-3
 
  
 
was subcloned into Nde 1 and Xho
1 sites of the bacterial expression vector pET-14b (Novagen).
 
Escherichia coli
 
 strain BL21(DE3) cells were transformed and cul-
tured at 37
 
 
 
C in Terrific Broth. The induction of expression was
started at an OD600 of 0.8–1.0 by the addition of 0.4 mM, iso-
propyl 
 
 
 
-D-thiogalactoside with continued incubation of the
culture at 37
 
 
 
C for 2–3 h. The bacterial pellets were resuspended
and sonicated in a buffer containing 5 mM imidazole, 500 mM
NaCl, and 20 mM Tris-HCl, pH 7.9. After centrifugation, the
cleared supernatants were passed through a His-Bind nickel aga-
rose affinity chromatographic column precharged with 50 mM
NiSO4 (Novagen). The columns were washed with wash buffer
containing 60 mM imidazole, 500 mM NaCl, and 20 mM Tris-
HCl, pH 7.9. His-tagged tBid was eluted with elution buffer
containing 400 mM imidazole, 500 mM NaCl, and 20 mM Tris- 
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Cl, pH 7.9, and was further purified using a Sephadex G-50 col-
umn equilibrated with PBS.
The plasmid pGEX2TKBak
 
 
 
C encoding COOH-terminal
truncated Bak (missing the last COOH-terminal 21 residues) as a
glutathione S-transferase (GST) fusion protein was a gift from
Thomas Chittenden (Apoptosis Technology Inc., Cambridge,
MA). 
 
Escherichia coli
 
 strain DH5
 
 
 
 (GIBCO BRL) cells were trans-
formed and cultured in LB medium. When the OD600 reached
0.7–1.0, isopropyl 
 
 
 
-D-thiogalactoside was added at a concentra-
tion of 0.1 mM to induce the expression of the fusion protein.
Bacteria were harvested after a 2–3 h incubation at 37
 
 
 
C and
lysed by sonication in lysis buffer (1% Triton X-100, 1 mM
EDTA in PBS). After centrifugation, the supernatant was incu-
bated with preswollen glutathion beads for 30 min at 4
 
 
 
C. The
beads were spun down and washed. GST-Bak
 
 
 
C was eluted
with 5 mM glutathione in 50 mM Tris-HCl, pH 8.0. As reported
previously (29), the deletion of the COOH-terminal 21 residues,
which encompass the transmembrane domain, did not interfere
with the insertion of Bak into the mitochondrial outer membrane
when directly applied to purified mitochondria.
 
Cell Lines and Clones.
 
Jurkat T leukemic cell line was ob-
tained from American Type Culture Collection. Jurkat cells were
grown in RPMI 1640 medium containing 10% FCS, 2 mM
 
L
 
-glutamine, and 100 U/ml each of penicillin and streptomycin
(complete medium). The Bak-deficient Jurkat clonal cell line was
isolated from wild-type Jurkat cells. Neo and Bcl-X
 
L
 
-transduced
Jurkat cells were a gift from Craig B. Thompson, Abramson Fam-
ily Cancer Research, Philadelphia, PA.
 
Transduction of Jurkat cells by Ad/GT-Bak and Ad/GV16.
 
Construction of Ad/GT-LacZ, Ad/GT-Bak, and Ad/GV16 was
reported previously (30, 31). This binary adenoviral vector system
was used to overcome Bak-mediated apoptosis in the packaging
293 cell line. In this binary system, the vector Ad/GT-Bak con-
tains a Bak gene under the control of the GAL4/TATA (GT)
promoter and the GAL4/VP16 (GV16) fusion protein. Bak gene
expression could then be induced in target cells by coadministra-
tion of the Ad/GT-Bak vector with the second adenoviral vector
Ad/GV16, which produces the GAL4/VP16 fusion protein. The
transduction efficiencies of the adenoviral vectors were deter-
mined by assessing the titer needed to infect the cells with Ad/
GT-LacZ and Ad/GV16.
 
GrB-induced Apoptosis.
 
CTL-free apoptosis was induced by
incubation of target cells with GrB (1–5 
 
 
 
g/ml) and replication-
deficient Ad type V (10–100 pfu/ml) for 15 min to 24 h. Apop-
tosis was measured by flow cytometric assessment of phosphati-
dylserine externalization in cells stained with annexin V-FITC in
combination with propidium iodide.
 
Western Blot Analysis.
 
To generate whole cell extracts, cells
were lysed in 0.5–1% NP-40, 10 mM Hepes, pH 7.4, 142 mM
KCl, 5 mM MgCl
 
2
 
, 1 mM EGTA, 1 mM PMSF, 10 
 
 
 
g/ml leu-
peptin, and 10 
 
 
 
g/ml aprotinin. Proteins were resolved by SDS/
PAGE and transferred to PVDF membranes, as described previ-
ously (32). After probing with a specific primary Ab and horse-
radish peroxidase-conjugated secondary Ab, the protein bands
were detected by enhanced chemiluminescence (Pierce Chemical
Co.).
 
Mitochondria Purification.
 
To obtain purified mitochondria,
Jurkat cells were suspended in mitochondria buffer (MIB) com-
posed of 0.3 M sucrose, 10 mM MOPS, 1 mM EDTA, and 4
mM KH
 
2
 
PO
 
4
 
, pH 7.4, and lysed by Dounce homogenization as
described previously (33). Briefly, nuclei and debris were re-
moved by 10 min centrifugation at 650 
 
g
 
 and a pellet containing
mitochondria was obtained by two successive spins at 10,000 
 
g
 
for 12 min. To obtain the S-100 fraction, the postnuclear super-
natant was further centrifuged at 100,000 
 
g
 
 for 1 h at 4
 
 
 
C. To
obtain purified mitochondria, the mitochondrial pellet was re-
suspended in MIB and layered on a Percoll gradient consisting of
four layers of 10%, 18%, 30%, and 70% Percoll in MIB. After
centrifugation for 35 min at 13,500 
 
g
 
, the purified mitochondria
were collected at the 30/70 interface. Mitochondria were di-
luted in MIB containing 1 mg/ml BSA (at least a 10-fold dilu-
tion required to remove Percoll). The mitochondrial pellet was
obtained by a 30-min spin at 20,000 
 
g
 
 and used immediately.
When indicated, mitochondria were pelleted, then incubated in
100 
 
 
 
l 0.1 M Na
 
2
 
CO
 
3
 
, pH 11.5, for 20 min on ice to remove
loosely attached proteins (34). After alkali treatment, superna-
tants and mitoplasts were separated by centrifugation and dis-
solved in 0.5% NP-40 lysis buffer. The fractions were analyzed
by immunoblotting.
 
Cytochrome c Release Assay.
 
Purified mitochondria (100 
 
 
 
g
protein) were incubated with recombinant His-tBid or GST-
Bak
 
 
 
C at various doses as indicated, in 100 
 
 
 
l MIB at 30
 
 
 
C for
30 min. Mitochondria were pelleted by centrifugation at 10,000
 
 g
 
for 5 min. The resulting supernatants or mitochondria were
mixed with lysis buffer and analyzed by SDS/PAGE and immu-
noblotting for the presence of cytochrome c.
 
Results
 
Deficient Expression of Bak Protein in Clonal Jurkat Cells.
 
A clonal cell line isolated from the ATCC wild-type Jurkat
cell line was found to be Bak-deficient. The deficiency was
determined by immunoblotting of whole cell lysates by
four different anti-Bak Abs (Fig. 1 A). To further analyze
the expression of Bak, lysates of wild-type or the clonal
Jurkat cells were fractionated to yield S-100 cytosol or pu-
rified mitochondria. These protein fractions were assessed
for the expression of Bak by Western blot analyses.
Whereas expression of Bak was detected in mitochondria
of wild-type Jurkat cells, only minor expression of Bak was
observed in a similar quantity of purified mitochondria
from Bak-deficient cells (Fig. 1 B). To assess the mitochon-
drial localization of Bak, purified mitochondria from either
wild-type or Bak-deficient cells were treated with alkali to
remove proteins nonspecifically attached to the mitochon-
dria (34). In wild-type Jurkat cells, Bak was found to be a
mitochondrial integral membrane protein, as it was de-
tected in the pellet of alkali-treated mitochondria (Fig. 1
B). Levels of protein expression of other Bcl-2 family
members in Bak-deficient cells, including Bcl-2, BCl-X
 
L
 
,
or Bax, were similar to those of the wild-type cell line (data
not shown).
 
Resistance of Bak-deficient Cells to GrB-mediated Apoptosis.
 
To study the susceptibility of Bak-deficient cells to GrB-
mediated cell death we used a CTL-free system, wherein
purified GrB was added in combination with a replication-
deficient Ad to the target cell suspension (5, 11, 35). Al-
though GrB enters the cell independently, via its surface
receptor (36), efficient apoptosis does not occur in the ab-
sence of perforin or a substituting Ad. As assessed by flow
cytometric analysis of cells stained with annexin V, treat-
ment of Jurkat cells for 2 h with a combination of GrB (1 
1328
 
A Role for Bak in Granzyme B–mediated Cytochrome c Release
 
 
 
g/ml) and Ad (10–100 pfu/ml) induced apoptosis in
wild-type, but not in Bak-deficient Jurkat cells (Fig. 2 A).
After GrB/Ad treatment for 24 h, 
 
 
 
20% of Bak-deficient
cells were annexin V-positive, as compared with 
 
 
 
80% of
wild-type cells (Fig. 2 B). Similar results (data not shown)
were obtained in cells treated with GrB and LAK extracts
that served as a source of perforin (37). These findings sug-
gest that despite the ability of GrB to initiate apoptosis at
multiple sites by direct cleavage of caspases or other apop-
tosis effector proteins, the major apoptotic mechanism of
GrB is blocked in our Jurkat Bak-deficient cells. Wild-type
cell apoptosis induced by 2-h treatment with GrB/Ad was
associated with cleavage of PARP and loss in DFF45/
ICAD expression (Fig. 2 C). In similarly treated Bak-defi-
cient cells, no cleavage of PARP or loss in DFF45/ICAD
was detected. To assess mitochondrial alterations associated
with GrB-mediated apoptosis, we used two fluorescent
dyes, which target different mitochondrial components.
After 2 h of treatment with GrB/Ad, the cells were stained
with the cationic lipophilic dye, chloromethyl X-rosamine
(CMXRos), to measure disruption of the mitochondrial
transmembrane potential. GrB/Ad treated wild-type, but
not Bak-deficient cells, demonstrated reduction in incor-
poration of this dye (Fig. 2 D). We also assessed mitochon-
drial changes by nonyl acrydine orange (NAO), which in-
teracts specifically with nonoxidized cardiolipin, a lipid that
is exclusively localized in the inner mitochondrial mem-
brane (38). Loss in cardiolipin was detected in wild-type
Jurkat cells treated with GrB/Ad, but not in Bak-deficient
cells (Fig. 2 E). These findings suggest that mitochondrial
apoptotic events induced in wild-type Jurkat cells by GrB
were blocked in our Bak-deficient cells. Despite their dif-
ferential susceptibility to GrB-mediated apoptosis both
wild-type and Bak-deficient Jurkat cells demonstrated sen-
sitivity to apoptosis induced by either TRAIL (Fig. 2 F) or
taxol (Fig. 2 G). TRAIL-mediated apoptosis is usually en-
hanced by a mitochondrial apoptotic loop (1), but may also
proceed via a caspase-dependent, mitochondria-indepen-
dent cascade. In accordance with this model, Bak-deficient
cells were TRAIL-sensitive, albeit at a decreased level rela-
tive to wild-type Jurkat cells. The reduced susceptibility of
Bak-deficient Jurkat cells to TRAIL may relate to the
block in the mitochondrial apoptotic loop in these cells
(Fig. 2 F). Wild-type and Bak-deficient Jurkat cells were
similarly susceptible to taxol (Fig. 2 G), suggesting that Bak
was not involved in the mechanism of cytotoxicity medi-
ated by this anticancer drug. These results suggest that Bak-
deficiency in Jurkat cells has a significant inhibitory effect
on GrB-mediated cytotoxicity, executed mainly by a mito-
chondrial apoptotic cascade.
 
Restored Susceptibility to GrB after Transduction of Bak-defi-
cient Cells with Ad/GT-Bak and Ad/GV16 Vectors.
 
Using
a binary adenoviral vector system to avoid the toxic effects
of Ad/Bak on the 293 packaging cells, we successfully pro-
duced large amounts of Ad/GT-Bak, whose gene product
(Bak) was under the transcriptional control of the GT pro-
moter and GV16 fusion protein (30, 31). The binary ade-
noviral LacZ vector system (Ad/GT-LacZ plus Ad/GV16)
Figure 1. Deficient expres-
sion of Bak in a clonal Jurkat cell
line. (A) Wild-type or the variant
Jurkat cell line, Bak , were incu-
bated in 1% NP-40 lysis buffer
for 30 min at 4 C. The resultant
lysates which contained both cy-
toplasm and mitochondria, were
resolved by SDS/PAGE and as-
sessed by immunoblotting for the
presence of Bak. Four different
anti–human Bak Ab were used
for blotting. The membranes
were stripped and reprobed for
 -actin to demonstrate equal
loading. (B) Expression of Bak in
mitochondria of wild-type, but
not in mitochondria of Bak-defi-
cient Jurkat cells. Expression of
Bak was examined in cytosol (S-
100), purified mitochondria, or
purified mitochondria treated
with alkali to remove nonspecifi-
cally attached proteins. These cell
fractions were resolved by SDS/
PAGE and immunoblotted se-
quentially by Bak-specific Ab-1
and Ab-2. After additional strip-
ping, the membranes were
probed with anti–Cox IV Ab, as
a marker for mitochondrial frac-
tions, and with anti– -actin as a
marker for cytosolic proteins. 
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was used to determine transduction efficiency. As detected
by immunoblotting, Bak expression was induced when
Ad/GT-Bak plus Ad/GV16 were administered, but not
when Ad/GT-LacZ plus Ad/GV16 were used (Fig. 3 A).
High level expression of Bak has been reported to induce a
rapid cell death (39). As assessed by flow cytometry of cells
stained with FITC-conjugated annexin V, we also ob-
served a substantial level of apoptotic cell death (
 
 
 
35%) in
both wild-type and Bak-deficient Jurkat cells 24 h after
transduction with Ad/GT-Bak plus Ad/GV16 vectors, but
not in mock infected cells (Fig. 3 B). Whereas Bak-defi-
cient cells were resistant to GrB-mediated apoptosis, a sig-
nificant increase in susceptibility (up to 
 
 
 
90%) was de-
tected in cells transduced with the Bak gene, but not in
control cells transduced with LacZ (Fig. 3 B). Apoptosis
was also confirmed by detection of active caspase-3 sub-
units and PARP cleavage in Bak-deficient cells infected
with Bak, but not in mock-infected cells similarly treated
(Fig. 3 A). Increased loss in prodomain caspase-3 or PARP
was detected in cells infected with Bak and treated with
GrB. Interestingly, the p20 subunit of caspase-3, but not
the p19 or p17 subunits, was also detected in LacZ trans-
duced cells treated with GrB. This subunit represents the
direct cleavage of caspase-3 by GrB (6, 40). However, the
partially activated caspase-3 was not sufficient to induce
apoptosis, as assessed by annexin V staining (Fig. 3 B) or
PARP cleavage (Fig. 3 A). These results confirm the role of
Bak deficiency in the observed resistance of these cells to
GrB/Ad-mediated apoptosis.
 
Abrogation of Cytochrome c release in Bak-deficient Mitochon-
dria.
 
GrB-mediated cytochrome c release has recently
been reported to be regulated by the Bcl-2 family mem-
ber, Bid (15–17). The initiation of apoptosis by GrB has
been reported to require direct cleavage of Bid, and the
translocation of the cleaved product to the mitochondria,
where it induces release of cytochrome c. Caspase-8–
Figure 2. Resistance of Bak-deficient Jurkat cells to GrB-mediated apoptosis. (A) and (B) Flow cytometry analysis of staining by annexin V of Jurkat
cells treated with Ad (10 PFU/ml), GrB (1  g/ml), and a combination of GrB and Ad for 2 h (A) or 24 h (B) at 30 C. The data are means   SD of re-
sults obtained in five independent experiments. The asterisks indicate a statistically significant difference between wild-type and Bak-deficient cells (P  
0.05, Mann-Whitney U). (C) GrB-mediated cleavage of PARP and DFF45/ICAD in wild-type, but not in Bak-deficient cells. Wild-type and Bak-defi-
cient cells were treated with Ad, GrB, or a combination of GrB and Ad, as described previously. The cell extracts were resolved on SDS/PAGE and im-
munoblotted with anti-PARP mAb or anti-DFF45/ICAD Ab. (D) and (E) Lack of mitochondrial apoptotic events in Bak-deficient Jurkat cells treated
with GrB. After 2 h of treatment with GrB and Ad, as described previously, the cells were assessed by flow cytometry for mitochondrial staining with
CMXRos or NAO. Staining with CMXRos (100 nM) served to assess changes in mitochondria permeability transition; staining with NAO (100 nM)
served to assess loss in mitochondrial cardiolipin. (F) and (G) Susceptibility of Bak-deficient Jurkat cells to TRAIL or taxol. Wild-type or Bak-deficient
Jurkat cells were treated with TRAIL (100 ng/ml) or taxol (10  g/ml) for 16 h. The cells were then analyzed by flow cytometry for staining by annexin
V or propidium iodide. Percentage of apoptotic cells are indicated for TRAIL. 
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cleaved Bid has been reported to require mitochondrial
Bak for cytochrome c release (25). To further explore the
possibility that the block in the response of our Bak-defi-
cient cells to GrB cytotoxicity was related to the require-
ment of mitochondrial Bak for Bid function, we exam-
ined the ability of a recombinant tBid that corresponds in
amino acid sequence to GrB-cleaved Bid (Ser
 
76
 
 to Asp
 
195
 
)
to induce cytochrome c release from purified mitochon-
dria. In contrast to mitochondria from wild-type Jurkat
cells, mitochondria obtained from Bak-deficient cells that
were treated with Ser
 
76
 
 to Asp
 
195
 
 recombinant tBid did
not release cytochrome c (Fig. 4 A). However, release of
cytochrome c was observed when purified mitochondria
from either wild-type or Bak-deficient cells were treated
with recombinant Bak (GST-Bak
 
 
 
C, Fig. 4 B). Cyto-
chrome c release in response to recombinant Bak was in-
hibited in mitochondria purified from Jurkat cells overex-
pressing Bcl- X
 
L
 
 (Fig. 4 B). These results suggest that the
resistance of Bak-deficient Jurkat cells to GrB-mediated
apoptosis is associated with the abrogation of cytochrome
c release by these mitochondria in response to GrB-
cleaved Bid.
 
Bid, but not Bax, Is Required for GrB-mediated Cytochrome c
Release.
 
The cleaved products of Bid generated by either
caspase-8 or GrB have been reported to induce the translo-
cation and insertion of cytosolic Bax into the outer mito-
chondrial membrane (16, 28). To determine the require-
ment for Bid and/or Bax in GrB-mediated release of
mitochondrial cytochrome c, we used liver mitochondria
from either Bid
 
 
 
/
 
 
 
, Bax
 
 
 
/
 
 
 
, or Bid
 
 
 
/
 
 
 
Bax
 
 
 
/
 
 
 
 mice (41,
42). Purified liver mitochondria were incubated with their
autologous cytosolic S-100 fractions in the presence or ab-
sence of GrB (1 
 
 
 
g/ml, 1 h, 30
 
 
 
C). GrB induced the re-
lease of cytochrome c when incubated with mitochondria
and S-100 fractions from either wild-type or Bax
 
 
 
/
 
 
 
 cells
(Fig. 5, lane 6). No release of cytochrome c was detected
with mitochondria obtained from Bid
 
 
 
/
 
 
 
 or Bax
 
 
 
/
 
 Bid / 
mice (Fig. 5, lane 6). The knockout murine model con-
firms the requirement for Bid in GrB-mediated cyto-
chrome c release. It appears that although Bax translocates
Figure 3. Restoration of apoptotic re-
sponse to GrB after Bak gene transduction.
(A) Bak expression, caspase-3 activation and
PARP cleavage after adenoviral-mediated
transduction of Bak. 24 h after infection of
Bak-deficient cells with the indicated com-
binations of adenoviral vectors, cell extracts
were assessed by immunoblotting for Bak
expression. The membrane was stripped and
reprobed for caspase-3 activation, stripped
again, and reprobed with anti-PARP mAb.
The p20 caspase-3 subunit in LacZ trans-
duced cells represents the direct cleavage of
caspase-3 by GrB. (B) Susceptibility of Bak-
deficient cells to GrB 24 h after adenoviral
transduction with Bak, but not with LacZ
gene. The presence of apoptotic cells was
assessed by annexin V staining of wild-type
or Bak-deficient cells infected with the in-
dicated combinations of adenoviral vectors
and treated with GrB (1  g/ml). Percentage
of annexin V-positive cells is indicated.1331 Wang et al.
to the mitochondria in response to tBid (16), this process is
not essential for GrB-mediated cytochrome c release. As
direct application of Bak to purified mitochondria induces
release of cytochrome c, we examined whether it would
synergize with GrB in the setting of mouse S-100 and mi-
tochondria. Mitochondria from the various mice tested, re-
sponded with minor release of cytochrome c when treated
with a low dose of recombinant Bak (Fig. 5, lane 7). How-
ever, synergy between recombinant Bak and GrB in release
of cytochrome c was observed only in wild-type or Bax / 
mitochondria (Fig. 5, lane 8).
A Direct, Caspase-independent Cleavage of Bid Is Unaltered
in Bak-deficient Cells. Our findings suggest that the block in
response of Bak-deficient Jurkat cells to GrB localizes to
the cytochrome c release mechanism within the mito-
chondria of these cells. To ensure that the function of Bid
upstream of the mitochondria is unaltered, we examined
Bid expression and its translocation to the mitochondria of
Bak-deficient cells. We first compared the kinetics of Bid
cleavage in wild-type and Bak-deficient Jurkat cells
treated with a combination of GrB and Ad. Exposure for
15 min of either wild-type or Bak-deficient cells to GrB/
Ad was sufficient for processing of significant portion of
full-length Bid present in these cells (Fig. 6 A and B).
These results demonstrate that Bid cleavage is unaffected
by Bak-deficiency. Under the conditions employed, pro-
teolytic processing occurred more readily with Bid than
with DFF45/ICAD (Fig. 2 C), reported to be a direct
substrate for GrB. To ensure that the observed cleavage of
Bid was directly mediated by GrB, rather than via GrB-
activated caspases, cleavage of Bid was also examined in
cells pretreated with the pan-caspase inhibitor, Z-VAD-
FMK. Similar kinetics and levels of processing were ob-
served in wild-type or Bak-deficient Jurkat cells in the ab-
sence or presence of Z-VAD-FMK (Fig. 6 C and D).
These results suggest that GrB-mediated cleavage of Bid
can proceed in a caspase-independent manner. To control
for the activity of caspase-3 in GrB-treated cells, the same
membranes (Fig. 6) were stripped and reprobed with anti-
caspase-3 Ab. In wild-type Jurkat cells, p19 and p17 cas-
pase-3 subunits were detected after 1–2 h of exposure to
Figure 4. Abrogation of cytochrome c release in Bak-deficient mito-
chondria in response to recombinant GrB-cleaved Bid. (A) Purified mi-
tochondria (100  g) obtained from wild-type or Bak-deficient Jurkat
cells were treated with his-tBid (Ser76-Asp195) at the indicated concentra-
tions for 30 min at 30 C. The supernatants (Mit-Sup) were boiled in re-
ducing Laemmli buffer, and assessed by immunoblotting for the presence
of cytochrome c. Lysed mitochondria from each of the two cell lines
tested served as positive controls. (B) Release of cytochrome c by mito-
chondria from either wild-type or Bak-deficient Jurkat cells is induced
by recombinant Bak and inhibited by Bcl-XL. Purified mitochondria
from wild-type, Bak-deficient, and Neo- or Bcl-XL–transduced cells
were incubated with GST-Bak C at the indicated concentrations for 30
min at 30 C. The presence of cytochrome c in the supernatants was as-
sessed as described previously.
Figure 5. Bid, but not Bax, is essential for GrB-mediated release of mi-
tochondrial cytochrome c. Purified mitochondria and S-100 cytosol frac-
tions were obtained from mouse livers of wild-type, or knockout mice,
including Bid / , Bax / , and Bid / Bax / . Purified mitochondria
were coincubated with autologous S-100 fractions in the presence or ab-
sence of GrB (5  g/ml) and GST-Bak C (4  M) for 30 min at 30 C.
Supernatants containing mitochondrial proteins were resolved by SDS/
PAGE and assessed by immunoblotting for the presence of cytochrome c.1332 A Role for Bak in Granzyme B–mediated Cytochrome c Release
GrB/Ad (Fig. 6 A). However, in the presence of Z-VAD-
FMK, only the p20 caspase-3 subunit, a direct cleavage
product of GrB was detected (Fig. 6 B). The absence of
p19 and p17 caspase-3 subunits, suggests that the p20 sub-
unit is unable to undergo further processing in the pres-
ence of Z-VAD-FMK. Interestingly, in Bak-deficient cells
only the p20 caspase-3 subunit was detected in either the
presence or the absence of Z-VAD-FMK. To assess the
activity of p20 caspase-3, the same samples were examined
for the presence of cleavage products of PARP. Cleavage
of PARP was detected only in wild-type Jurkat cells,
where full processing of caspase-3 was detected (Fig. 6 A).
Caspase-3 p20 detected in wild-type cells in the presence
of Z-VAD-FMK, or in Bak-deficient cells appears to be
relatively inactive as it failed to cleave PARP (Fig. 6 B–D).
In contrast to PARP or DFF45/ICAD whose efficient
processing required the presence of both GrB and Ad (Fig.
2 C), Bid cleavage was observed also in cells treated with
GrB only. These results further demonstrate that Bid is a
preferred substrate for GrB, which upon cell internaliza-
tion cleaves Bid even in the absence of facilitation by
an Ad.
Next, we treated Dounce homogenized extracts of
wild-type, Bak-deficient, Neo, and BCl-XL transduced
Jurkat cells with GrB (1  g/ml, 1 h, 30 C). The extracts
were then separated into cytosol S-100 and mitochondria
fractions. GrB treatment resulted in complete processing
of Bid, as full-length Bid was not detected in the cytosols
obtained from GrB-treated extracts of all the variants of
Jurkat cells examined (Fig. 7 A). Thus, Bak-deficiency or
overexpression of Bcl-XL do not affect GrB-mediated pro-
cessing of Bid. Interestingly, full processing of caspase-3
was detected in the cytosol fraction of Bak-deficient cell
extracts treated with GrB (Fig. 7 B). To ensure that Bid
cleavage was not mediated by GrB-activated caspase-3, the
extracts were treated with Z-VAD-FMK (100  M, 20
min) before the addition of GrB. Similar processing of Bid
was also observed in the presence of the caspase inhibitor
(Fig. 7 B). In the presence of Z-VAD-FMK, only p20 cas-
pase-3 was detected in extracts of Bak-deficient cells,
whereas both p19 and p17 caspase-3 subunits were de-
tected in the absence of the inhibitor. Thus, in contrast to
GrB-treated Bak-deficient cells, in treated extracts full
processing of caspase-3 was observed. It appears that the
application of GrB directly into the extracts results in a
higher dose than would have been internalized via the cell
membrane. Such an augmented dose of GrB seems to
overcome the lack of mitochondrial contribution to cas-
pase-3 processing in Bak-deficient cells. The cleavage
product of Bid was detected in the mitochondria obtained
Figure 6. GrB-mediated cleavage of Bid is unaltered in
Bak-deficient cells and proceeds in the presence of a potent
caspase inhibitor. Wild-type and Bak-deficient Jurkat cells
were treated with Ad (10 PFU/ml) or GrB (1  g/ml) for
2 h, or with a combination of GrB and Ad for various time
periods as indicated. In A and B, the cells were treated in
the absence of caspase inhibitors. In C and D, the cells
were pretreated with Z-VAD-FMK (100  M) for 2 h be-
fore exposure to Ad, GrB, or GrB/Ad. A DMSO control
for the solvent of Z-VAD-FMK is included in C and D.
At the end of the incubation periods, the cells were lysed,
resolved by 15% SDS/PAGE, and immunoblotted for the
presence of Bid and its cleavage products. Each of the
membranes was sequentially stripped and reprobed with
anticaspase-3 and anti– -actin Ab. For the detection of
PARP, the same samples were resolved by 7.5% SDS/
PAGE. Please note, the presented  -actin serves as a load-
ing control for Bid and caspase-3 (not for PARP).1333 Wang et al.
from extracts of Bak-deficient cells treated in the presence
or the absence of Z-VAD-FMK (Fig. 7 C). These results
suggest that GrB-cleaved Bid targets the mitochondria
within the cell extract. Together, the results shown in
Figs. 6 and 7 suggest that the block in GrB-mediated cyto-
chrome c release in Bak-deficient cells is downstream of
GrB-cleaved Bid translocation to the mitochondria.
GrB-mediated Cytochrome c Release Is Abrogated in Bak-defi-
cient Mitochondria, but Restored in the Presence of Recombinant
Bak. To directly investigate the role of Bak in release of
mitochondrial cytochrome c in response to GrB, we com-
pared the response of wild-type and Bak-deficient mito-
chondria to autologous S-100 treated with GrB. Cyto-
chrome c was detected in the supernatant of wild-type
mitochondria, but not in supernatants of Bak-deficient mi-
tochondria, treated with S-100 cytosol and GrB (Fig. 8,
lane 6). However, in the presence of a low-dose of recom-
binant Bak, which by itself induced only minor release of
cytochrome c (Fig. 8, lane 7), an augmented release in re-
sponse to GrB was detected (Fig. 8, lane 8). Thus, the pres-
ence of recombinant Bak restored the capability of Bak-
deficient mitochondria to release cytochrome c in response
to GrB and cytosol.
Discussion
This study is the first to demonstrate that the mitochon-
drial proapoptotic Bcl-2 member, Bak, plays a role in GrB/
Ad-mediated cytochrome c release. Bak deficiency en-
dowed this Jurkat cell variant with a potent mechanism of
resistance to GrB/Ad-induced cell death. The significance
of Bak was confirmed by transduction of the Bak gene into
these cells, which restored susceptibility to GrB-mediated
apoptosis. The importance of Bak was further demon-
strated in a cell-free system, where GrB-treated S-100 did
not induce release of cytochrome c from Bak-deficient mi-
tochondria from the Jurkat cell variant unless recombinant
Bak was added.
GrB is a prominent mediator of the apoptotic cascade in-
duced by CTLs or NK in a pathogenic cell. Its significance
in the execution of cytotoxic mechanisms against viral-
infected cells or allogeneic cells has been established in
studies performed in GrB-knockout mice (43–46). As GrB
is an aspase, which can cleave either caspases (47, 48) or
death substrates directly (37, 49, 50), it was thought to pro-
duce apoptotic events and morphology by short-circuiting
the death receptor or mitochondrial pathways of apoptosis.
However, in Bak-deficient Jurkat cells treated for up to 24 h
with a combination of GrB and Ad, a significant inhibition
of apoptosis was observed, whereas wild-type cells were
highly susceptible as early as 2 h after similar GrB treat-
ment. These findings suggest that the Bak deficiency serves
to block the prominent pathway used by GrB to initiate
target cell apoptosis. As Bak represents a mitochondrial
protein involved in the mechanism of cytochrome c re-
lease, our results imply that a mitochondrial pathway of
apoptosis is preferentially activated by GrB to induce apop-
tosis. Consistent with our findings, it has recently been
Figure 7. GrB-mediated cleavage
of Bid and its translocation to the
mitochondria in extracts of Bak-
deficient cells. (A) Jurkat cell lines,
including wild-type, Bak-deficient,
Neo-, or Bcl-XL–transduced cells
were Dounce homogenized, and
then treated with GrB (1  g/ml) for
1 h at 30 C. The extracts were then
separated into S-100 cytosol and mi-
tochondria fractions. Loss of full-
length Bid was detected in cytosols
of all Jurkat cell variants treated with
GrB. The anti-BID Ab used for this
blot detects only full length Bid. (B)
GrB-mediated cleavage of Bid pro-
ceeds in the presence of Z-VAD-
FMK. Extracts of Bak-deficient
Jurkat cells were incubated with
Z-VAD-FMK (100  M) for 20
min before the addition of GrB (1
 g/m) for 1 h at 30 C. The extracts
were then fractionated into S-100
and mitochondrial fractions, which
were assessed by immunoblotting
and sequential probing for the pres-
ence of Bid, caspase-3, and  -actin.
(C) Translocation of GrB-cleaved
Bid to the mitochondria of Bak-
deficient Jurkat cells. The mito-
chondrial fraction of extracts of Bak-
deficient cells treated with GrB in the presence or absence of Z-VAD-FMK was assessed by immunoblotting for the presence of tBid. The membrane
was stripped and reprobed with anti-Cox IV mAb, as a mitochondrial marker and to demonstrate equal loading.1334 A Role for Bak in Granzyme B–mediated Cytochrome c Release
concluded that the preferred mechanism for rapid induc-
tion of apoptosis by GrB is via initiation of a mitochondrial
cascade inhibitable by Bcl-2 (13, 15, 16). Using time lapse
confocal microscopy it was demonstrated that mitochon-
drial cytochrome c release is the primary mode of GrB-
induced apoptosis (13). Caspase activation was not required
for the observed release of cytochrome c, which was medi-
ated by Bid cleavage and its translocation to the mitochon-
dria. GrB was found to cleave Bid more readily than it
cleaves either caspase-3 or -8 (13). We also observed that
Bid was the preferred GrB substrate as compared with
DFF45/ICAD. Cleavage of DFF45/ICAD by either cas-
pase-3 or GrB, dismantles its inhibitory activity and facili-
tates its assembly into an active form of DNase (37, 51, 52).
Exogenous GrB at a dose which was sufficient to enter the
cells and induce Bid processing in 15 min, was too low to
directly cleave DFF45/ICAD even after 2-h incubation.
This DNase precursor was readily processed in wild-type
Jurkat cells, suggesting that DFF45/ICAD processing was
enhanced by the mitochondrial release of cytochrome c in-
duced by GrB in wild-type cells, but not in Bak-deficient
cells. The cleavage of Bid by GrB represents a caspase-
independent event upstream of the mitochondria, as similar
kinetics and processing were observed in the presence or
the absence of a potent caspase inhibitor in either wild-type
or Bak-deficient cells.
The requirement for Bid in GrB-mediated mitochon-
drial cascade was demonstrated by various experimental ap-
proaches, including the immunodepletion of Bid from cy-
tosolic extracts before the addition of mitochondria and
GrB (16), or by the inability of Bid with a mutated GrB
cleavage site to restore the response to GrB in Bcl-2 over-
expressing cells (15). Bid requirement was confirmed in the
current study by a Bid knockout murine model. We also
used a Bax knockout model to determine its role in the
GrB apoptotic cascade. In contrast to Bid, the expression of
Bax was not essential for GrB-mediated cytochrome c re-
lease. Although Bax does not appear to be required for the
GrB mitochondrial cascade, its translocation to the mito-
chondria as observed in Jurkat cells by Heibien et al. (16),
suggests that it plays a facilitating role in the mitochondrial
response to GrB.
Bak, a mitochodrial proapoptotic Bcl-2 family member
is required for the mechanism of cytochrome c release in
response to caspase-8 cleaved Bid (25). The exact nature of
the interaction between caspase-8–cleaved Bid and Bak has
not yet been fully resolved. Using murine Bak-deficient
mitochondria or by treating Bak-containing mitochondria
with an anti-Bak blocking Ab, tBid was found to bind in a
transient manner to mitochondrial Bak and to release cyto-
chrome c (25). As a result of this interaction, Bak under-
goes allosteric activation and an intramembraneous oligo-
merization into a proposed pore for cytochrome c efflux
(25, 26). This study demonstrates that GrB-cleaved Bid can
also utilize Bak to induce the release of mitochondrial cy-
tochrome c. Thus, using either human Bak-deficient Jurkat
cells or a cell-free system composed of Bak-deficient mito-
chondria and cytosol derived from these cells, our findings
have established an unequivocal role for Bak in the mito-
chondrial response to GrB. In these two experimental sys-
tems, the crucial role of Bak was confirmed by a gain in
susceptibility to GrB after restoration of Bak expression.
The mechanism of interaction between GrB-cleaved Bid
and Bak has not yet been studied.
Partial activation of caspase-3, demonstrated by the ap-
pearance of partially processed p20 form, a product of the
direct cleavage of procaspase-3 by GrB at D175 (6, 15, 40),
was detected over a 15-min exposure to GrB of either
wild-type or Bak-deficient Jurkat cells. However, further
processing to the p19 and p17 subunits of caspase-3 over a
2-h incubation was only observed in wild-type, but not in
Bak-deficient cells. As judged by its inability to cleave
PARP, the GrB-generated p20 caspase-3 is relatively inac-
tive, and requires mitochondrial factors to achieve full-pro-
cessing and activation. Similar observations were made by
Sutton et al. in Bcl-2 overexpressing cells (15). These au-
thors speculated that in the absence of mitochondrial per-
turbation, the XIAP inhibitor, SMAC/DIABLO, was not
released into the cytosol, allowing cytosolic XIAP to main-
tain caspase-3 in an inactive form (53, 54). In accordance
with this model, exposure of Bak-deficient cells to exoge-
nous GrB resulted only in the first stage of procaspase-3
processing, suggesting that cytochrome c or other mito-
chondrial factors, such as SMAC, were required for further
Figure 8. Restoration of GrB-mediated cytochrome c release from
Bak-deficient Jurkat mitochondria in the presence of recombinant Bak.
Purified mitochondria and S-100 cytosol fractions obtained from wild-
type or Bak-deficient Jurkat cells were treated with GrB (1  g/ml) and/
or GST-Bak C (2  M) for 30 min at 30 C. The supernatants were as-
sessed by immunoblotting for the presence of cytochrome c. The mem-
branes were stripped and reprobed with anti– -actin Ab.  -actin, a cyto-
solic protein, was detected in S-100, and not mitochondria-only fractions.1335 Wang et al.
caspase-3 processing. However, we observed full caspase-3
processing in extracts of Bak-deficient cells directly treated
with exogenous cytochrome c (data not shown). These
findings suggest that an overdose of cytochrome c (which
may reflect a nonphysiologic situation) overcomes the lack
of SMAC. In a similar manner, we also observed full pro-
cessing of caspase-3 in extracts of Bak-deficient cells treated
directly with GrB in the absence of Z-VAD-FMK, but not
in the presence of this pan-caspase inhibitor. These results
suggest that the second stage of caspase-3 processing may
be achieved in a mitochondria-independent manner in the
presence of an augmented dose of GrB, which should be
higher than that internalized via its cell surface receptor.
Bid-deficient mice revealed that Bid is a critical caspase
substrate for FasL- or TNF- –induced death of hepato-
cytes in vivo (41). Thus, in hepatocytes, and probably other
types of target cells in which caspase-8 is not efficiently re-
cruited to the DISC (55), a loss in Bid expression may serve
to block Fas-dependent cytotoxic mechanisms of CTLs and
NK cells. The crucial requirement for Bid in GrB-medi-
ated apoptosis suggests that downregulation of Bid expres-
sion will also block a major step in apoptosis triggered by
granule exocytosis by CTLs and NK cells. Our findings
suggest that deficiency in Bak expression may serve as an
efficient mechanism of immune evasion for tumor or viral
infected cells, as it blocks GrB-mediated cytotoxicity, and
in certain cell types also blocks the Bid-dependent Fas
pathway, two major cytotoxic mechanisms used by CTLs
and NK cells.
A recent report (20) has identified Bid as a sensor of
proteolysis by an endopeptidase, which triggers the mito-
chondrial mechanism of cytochrome c release. Thus,
cleavage of Bid may represent a mechanism by which pro-
teases that have leaked from lysosomes can trigger cell
death. Bak-deficiency may serve to protect against such a
lysosomal pathology.
It is interesting to note that deficiency in Bak endows
Jurkat cells with a potent mechanism of resistance to certain
anticancer drugs (29). The significance of Bak for GrB-
mediated cytotoxicity suggests that Bak-deficient tumor
cells utilize this deficiency as a mechanism of resistance to
either cytotoxic drugs or to cytotoxic lymphocytes. These
findings may have an important implication for immuno-
therapy protocols, which target residual disease after treat-
ment with anticancer drugs. Bak deficiency may also inter-
fere with antitumor vaccine therapy, where the cytotoxic
activity of specific CTLs could be compromised by the dis-
abling of the GrB-mediated mitochondrial apoptotic cas-
cade in target cells.
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